Company CVAbout Astrazeneca Pharma India Ltd 
Astrazeneca Pharma India Ltd
Small Cap
Pharmaceuticals & Biotechnology
AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979. The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company. The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology.
Company Coordinates
Company Details
Blk N1 12th Flr Manyata Embass, Rachenahalli Outer Ring Road Bangalore Karnataka : 560045
Registrar Details
Integrated Enterprises (India) Ltd , 30, Ramana Residency, 4th Cross, Sampige Road, Malleswaram, Bangalore
Capital StructureCapital Structure
Present Equity Capital
INR None Cr
Number of Shares
None Cr
Face Value
INR None
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
No Details Available.
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Promoters
Pledged Promoter Holdings
None
Mutual Funds
Held by 20 Schemes (5.0%)
FIIs
Held by 100 FIIs (2.74%)
Promoter with highest holding
Astrazeneca Pharmaceuticals Ab (75.0%)
Highest Public shareholder
Nippon Life India Trustee Ltd-a/c Nippon India Small Cap Fund(various Schemes) (2.92%)
Individual Investors Holdings
14.39%
Board of Directors
Management
Designation
Remuneration
Narayan K Seshadri
Chairman & Independent Directo
14.0 lacs
Revathy Ashok
Non-Exec. & Independent Dir.
12.0 lacs
Rajesh Marwaha.
Whole Time Director & CFO
4.25 cr
Weiying Sarah Wang
Non Executive Director
0
Ankush Nandra
Non Executive Director
0
Shilpa Divekar Nirula
Non-Exec. & Independent Dir.
13.0 lacs
Sanjeev Panchal
Managing Director
57.91 lacs
Hooi Bien Chuah
Non Executive Director
0
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
No Data Available for Raw Material Segmentation
No Data Available
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Tablets
637.12
87.48%
Injectables
35.73
4.91%
Sale of Services - Clinical Trials
23.62
3.24%
Tablets
Tablets
Injectables
Injectables
Sale of Services - Clinical Trials
Sale of Services - Clinical Trials
Stock DNARevenue and Profits:
Net Sales:
559 Cr
(Quarterly Results - Sep 2025)
Net Profit:
54 Cr
Pharmaceuticals & Biotechnology
INR 22,770 Cr (Small Cap)
99.00
34
0.35%
-0.46
29.06%
28.66
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
